See the DrugPatentWatch profile for Fondaparinux
What is Fondaparinux?
Fondaparinux is a synthetic pentasaccharide anticoagulant that selectively inhibits activated Factor X (FXa) [1]. It is a synthetic analog of the highly specific binding region of unfractionated heparin and low molecular weight heparins [2]. The drug works by binding to antithrombin III, which then inactivates FXa [1]. This action interrupts the coagulation cascade, thereby preventing the formation of blood clots [2].
How is Fondaparinux Used Medically?
Fondaparinux is prescribed to prevent and treat venous thromboembolism (VTE), which includes deep vein thrombosis (DVT) and pulmonary embolism (PE) [1]. It is used in patients undergoing hip fracture surgery, hip replacement surgery, knee replacement surgery, and abdominal surgery, as well as in those with acute medical illnesses who are at risk for thromboembolic complications [3]. It is also used to treat DVT and PE in combination with warfarin [1].
When Does Fondaparinux Patent Exclusivity Expire?
The original patent for fondaparinux, brand name Arixtra, expired on September 20, 2018, in the United States [4]. DrugPatentWatch.com tracks patent expiry dates for numerous medications, including fondaparinux, and provides information on when market exclusivity is expected to end [4].
What Are the Risks Associated with Fondaparinux?
The primary risks associated with fondaparinux are bleeding events [1]. Other potential adverse effects include anemia and dizziness. Contraindications include active major bleeding and severe hypersensitivity to the drug [3].
Are There Generic Versions of Fondaparinux Available?
Following the expiry of patent protection, generic versions of fondaparinux have become available [4]. The availability of generics can lead to lower drug costs for patients and healthcare systems.
How Does Fondaparinux Compare to Other Anticoagulants?
Fondaparinux offers a targeted mechanism of action by specifically inhibiting FXa. Unlike unfractionated heparin, it does not require regular laboratory monitoring for efficacy or safety [2]. Compared to direct oral anticoagulants (DOACs), fondaparinux is administered subcutaneously and has a different pharmacokinetic and pharmacodynamic profile [5]. Its use is generally limited to prophylaxis and treatment of VTE, while DOACs have broader indications for stroke prevention in atrial fibrillation and treatment of VTE [5].
Sources
1. https://www.drugpatentwatch.com/
2. https://www.drugpatentwatch.com/
3. https://www.drugpatentwatch.com/
4. https://www.drugpatentwatch.com/
5. https://www.drugpatentwatch.com/